filmov
tv
High-throughput DNA damage analyses identify synergistic drug combinations to treat malignant...
Показать описание
Presented By: Sachin Katyal, PhD
Speaker Biography: Sachin Katyal received his B.Sc. (Biochemistry) from the University of Alberta and received his Ph.D. (Oncology) at the Cross Cancer Institute and the University of Alberta. His post-doctoral training, at St. Jude Children’s Research Hospital, in the area of DNA damage and repair in neurodevelopment and neuro-oncology was done in the lab of Dr. Peter McKinnon; work that led to publications in internationally-renowned journals such as Nature, Nature Neuroscience and EMBO J. In 2013
Webinar: High-throughput DNA damage analyses identify synergistic drug combinations to treat malignant brain tumours
Webinar Abstract: Current methods to treat malignant brain tumors are highly intrusive, leading to poor quality of life with abysmal patient survival rates. Combined with radiation therapy, first/second-line DNA damaging chemotherapeutics marginally improve patient survival. However, high rates of drug-resistance and recurrence are due to development of intra/intertumoral heterogeneity due in part from the emergence of chemoradioresistant clones.
Speaker Biography: Sachin Katyal received his B.Sc. (Biochemistry) from the University of Alberta and received his Ph.D. (Oncology) at the Cross Cancer Institute and the University of Alberta. His post-doctoral training, at St. Jude Children’s Research Hospital, in the area of DNA damage and repair in neurodevelopment and neuro-oncology was done in the lab of Dr. Peter McKinnon; work that led to publications in internationally-renowned journals such as Nature, Nature Neuroscience and EMBO J. In 2013
Webinar: High-throughput DNA damage analyses identify synergistic drug combinations to treat malignant brain tumours
Webinar Abstract: Current methods to treat malignant brain tumors are highly intrusive, leading to poor quality of life with abysmal patient survival rates. Combined with radiation therapy, first/second-line DNA damaging chemotherapeutics marginally improve patient survival. However, high rates of drug-resistance and recurrence are due to development of intra/intertumoral heterogeneity due in part from the emergence of chemoradioresistant clones.
0:59:50
0:50:55
0:21:43
0:02:01
0:03:36
0:05:24
0:55:44
0:02:08
0:16:49
0:03:42
0:09:50
1:15:42
0:01:39
0:00:11
1:03:16
0:44:10
0:41:27
0:35:48
0:08:16
0:04:21
0:02:42
0:52:48
0:02:01
0:02:11